FIGO regularly issues statements and joint statements.

This World Prematurity Day, FIGO calls on healthcare providers, policymakers, and communities to champion better care for ...

We have recently witnessed some policy changes that have led to the expanded registration of mifepristone, a crucial ...

The International Journal of Gynecology & Obstetrics (IJGO) has published a special article by the FIGO Committee on Ethical ...

FIGO’s Accelerating Measurable Progress and Leveraging Investments for Postpartum Haemorrhage Impact (AMPLI-PPHI) project aims to dramatically reduce maternal mortality and morbidity from PPH.

Post-partum haemorrhage (PPH) is the leading cause of maternal mortality globally, accounting for over 20% of maternal deaths worldwide. Although PPH is largely preventable, it continues to ...

The 2021 edition of the FIGO Cancer Report contains updates on the management of gynaecological cancers combined with pertinent papers on gynaecological oncology, which we hope the reader will find ...

Each member society is committed to supporting FIGO's aim for women of the world to achieve the highest possible standards of physical, mental, reproductive and sexual health and wellbeing throughout ...

Worldwide, the growing use of contraceptive methods has led to a reduction in maternal and infant mortality, improvements in socio-economic conditions and increased schooling for girls and women.

May 2019, FIGO released Guidelines to combat pre-eclampsia, and calls for all women to receive first-trimester screening. Read the Pre-eclampsia Guidelines here. 76,000 women and 500,000 babies die ...

FIGO’s 2024-2025 free webinar series tackles the most pressing issues on women’s health and rights. Organised by FIGO’s Divisions and Committees, FIGO’s webinar series brings together women’s health ...